盐皮质激素拮抗与早期常染色体显性多囊肾病血管功能:随机对照试验
本研究为随机双盲安慰剂对照试验,纳入61例20-55岁、eGFR≥60mL/min/1.73m2且已用RAAS抑制剂的早期ADPKD患者,比较螺内酯(最大50mg/d)与安慰剂24周对血管功能的影响。结果显示螺内酯未改变肱动脉血流介导舒张(FMDBA)或颈股脉搏波速度(CFPWV),但降低了肱动脉收缩压。
要点
- 螺内酯24周未改善早期ADPKD患者FMDBA或CFPWV。
- 螺内酯使肱动脉收缩压中位变化较安慰剂组降低(P=0.04)。
- 基线血管功能障碍程度低,可能限制干预效果。
核心结论
- 24周盐皮质激素拮抗降低早期ADPKD患者收缩压,但未改变血管功能。
研究设计与样本
- 前瞻性、随机、对照、双盲临床试验,61例早期ADPKD成人随机接受螺内酯或安慰剂24周。
主要发现
- 螺内酯组FMDBA基线8.0%±5.5%、24周7.8%±4.3%,安慰剂组8.4%±6.2%、8.0%±4.6%,组间变化比较P=0.9。
- 螺内酯组CFPWV基线640±127cm/s、24周603±101cm/s,安慰剂组659±138cm/s、658±131cm/s,组间变化比较P=0.1。
- 螺内酯组肱动脉收缩压中位变化-6(IQR -15,1)mmHg,安慰剂组-2(IQR -7,10)mmHg,P=0.04。
- 螺内酯未改变多数循环和/或内皮细胞氧化应激/炎症标志物,也未改变血管氧化应激。
临床怎么用
- 早期ADPKD患者使用螺内酯24周可小幅降低收缩压,但不应期望改善血管内皮功能或动脉僵硬度。
局限性
- 基线血管功能障碍程度低。
- 未测量醛固酮水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Vascular dysfunction, characterized by impaired vascular endothelial function and increased large-elastic artery stiffness, is evident early in autosomal dominant polycystic kidney disease (ADPKD) and is an important predictor of cardiovascular events and mortality. Aldosterone excess has been implicated in the development of endothelial dysfunction and arterial stiffness, in part by causing increased oxidative stress and inflammation. We hypothesized that aldosterone antagonism would reduce vascular dysfunction in patients with early-stage ADPKD. STUDY DESIGN: Prospective, randomized, controlled, double-blind, clinical trial. SETTING & PARTICIPANTS: 61 adults aged 20 to 55 years with ADPKD, estimated glomerular filtration rate ≥ 60mL/min/1.73m2, and receiving a renin-angiotensin-aldosterone system inhibitor. INTERVENTION: Spironolactone (maximum dose, 50mg/d) or placebo for 24 weeks. OUTCOMES: Change in brachial artery flow-mediated dilation (FMDBA) was the primary end point and change in carotid-femoral pulse-wave velocity (CFPWV) was the secondary end point. RESULTS: 60 participants completed the trial. Participants had a mean age of 34±10 (SD) years, 54% were women, and 84% were non-Hispanic white. Spironolactone did not change FMDBA (8.0% ± 5.5% and 7.8% ± 4.3% at baseline and 24 weeks, respectively, vs corresponding values in the placebo group of 8.4% ± 6.2% and 8.0% ± 4.6%; P=0.9for comparison of change between groups) or CFPWV (640±127 and 603±101cm/s at baseline and 24 weeks, respectively, vs corresponding values in the placebo group of 659±138 and 658±131cm/s; P=0.1). Brachial systolic blood pressure was reduced with spironolactone (median change, -6 [IQR, -15, 1] vs -2 [IQR, -7, 10] mm Hg in the placebo group; P=0.04). Spironolactone did not change the majority of circulating and/or endothelial cell markers of oxidative stress/inflammation and did not change vascular oxidative stress. LIMITATIONS: Low level of baseline vascular dysfunction; lack of aldosterone measurements. CONCLUSIONS: 24 weeks of aldosterone antagonism reduced systolic blood pressure without changing vascular function in patients with early-stage ADPKD. FUNDING: NIDDK, NIH National Center for Advancing Translational Sciences, and the Zell Family Foundation. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT01853553.
引用
- Nowak KL, Gitomer B, Farmer-Bailey H, et al. Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial. Am J Kidney Dis. 2019. PMID: 30803706. doi:10.1053/j.ajkd.2018.12.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。